A Technically Sound Biomarker for axSpA, But Is It Aimed at the Right Patient Population?

Could this be developed to be a population screening test?

The persistent 5-to-10-year diagnostic delay in axial spondyloarthritis (axSpA) can lead to irreversible spinal damage. Limited access to tools like MRI and HLA-B27 typing has fueled the search for a simple, robust blood test to aid in earlier diagnosis (perhaps as a population screening tool). The 14-3-3η (eta) autoantibody (AAb) multiplex assay is one…